Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b randomized open-label aflibercept regimens in pre-treated DME
2014-004938-25Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Bayer. Primary endpoint: Change in ETDRS BCVA letter score for the study eye. Started Feb 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2014-004938-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004938-25.